HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Cross-resistance between voriconazole and fluconazole for non-albicans Candida infection: a case-case-control study.

Abstract
Cross-resistance (CR) between voriconazole and fluconazole for non-albicans Candida (NAC) species is not uncommon, but little is known about the risk factors and clinical consequences associated with this resistance phenotype. A case-case-control study was performed at a university-affiliated hospital in China between November 2012 and April 2016. The two case groups respectively comprised patients with a mono-resistance (MR) NAC infection (fluconazole or voriconazole resistance) and patients with a CR NAC infection (fluconazole and voriconazole resistance). Patients with a no-resistance (NR) NAC infection were included as the control group. Models were adjusted for demographic and clinical risk factors, and the risk of resistance associated with exposure to specific antibiotics or non-antibiotics were assessed. Of 259 episodes, 33 (12.7%) and 27 (10.4%) were identified as MR and CR NAC infections, respectively. The broad use of azoles was strongly associated with the emergence of MR and CR NAC infections (adjusted odds ratio [95% confidence interval] = 2.69 [1.10-6.58] and 2.53 [1.02-6.28], respectively). The time at risk (1.02 [1.00-1.03]) with 12 days as a breakpoint was also an independent risk factor for CR NAC infection. The number of species associated with a high minimum inhibitory concentration (≥128 μg/mL) of fluconazole was higher for CR NAC infections than for MR NAC infections. Different resistance phenotypes (CR vs. MR vs. NR) were associated with all-cause mortality rates. These findings indicate a worrisome propensity of CR NAC infections and emphasize the need for strict antifungal stewardship.
AuthorsY Wang, Q Yang, L Chen, L Liu, R Hao, T Zhang, X Wang, J Lei, J Xie, Y Dong
JournalEuropean journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology (Eur J Clin Microbiol Infect Dis) Vol. 36 Issue 11 Pg. 2117-2126 (Nov 2017) ISSN: 1435-4373 [Electronic] Germany
PMID28620845 (Publication Type: Journal Article)
Chemical References
  • Antifungal Agents
  • Fluconazole
  • Voriconazole
Topics
  • Aged
  • Antifungal Agents (therapeutic use)
  • Antimicrobial Stewardship
  • Candida (drug effects)
  • Candidiasis (drug therapy, microbiology)
  • Case-Control Studies
  • China
  • Drug Resistance, Multiple, Fungal (physiology)
  • Female
  • Fluconazole (therapeutic use)
  • Humans
  • Male
  • Microbial Sensitivity Tests
  • Middle Aged
  • Risk Factors
  • Voriconazole (therapeutic use)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: